Introduction
Wilms' tumor (WT), or nephroblastoma, is a pediatric malignancy of the kidney, and one of the most common solid cancers of childhood. The observation that sporadic cases differ from familial ones as for the age of onset and the frequency of bilateral presentation, led Knudson and Strong (1972) to propose that WT, like retinoblastoma, develops as a consequence of two ratelimiting events (two 'hits'), which subsequently were identified as the biallelic inactivation of a tumor suppressor gene.
The WT1 gene, which plays an important role in kidney embryogenesis (Pritchard-Jones et al., 1990) , perfectly fits within this model. In fact, patients affected with the WAGR (Wilms' tumor, aniridia, genitourinary abnormalities and mental retardation) or the DenysDrash syndromes, both predisposing to WT, carry germline heterozygous deletions or point mutations of WT1, which is completely inactivated in tumor DNA (reviewed in Little and Wells, 1997) . However, inactivating mutations of the gene are detectable only in a small fraction-not exceeding 15%-of sporadic WTs without congenital anomalies (Little and Wells, 1997; Schumacher et al., 1997; Little et al., 2004; Perotti et al., 2005a) . Interestingly, 50-75% of WT1-mutant WTs carry mutations also of the CTNNB1 gene, which codes for b-catenin, an important transcription regulator. However, such mutations are not usually detectable in WTs with wild-type WT1 alleles (Maiti et al., 2000; Li et al., 2004) . In the latter group, a number of studies, including cytogenetics, loss of heterozygosity (LOH) and comparative genomic hybridization (CGH) analyses, have revealed the involvement of different chromosomal regions. These include 11p15-where a cluster of imprinted genes, among which H19 and IGF2, is mapped (Reeve et al., 1989; Ogawa et al., 1993; Rainier et al., 1993 )-1p, 11q, 16q, 22q (Maw et al., 1992 Grundy et al., 1994; Radice et al., 1995; Klamt et al., 1998; Hing et al., 2001; Hoglund et al., 2004; Ruteshouser et al., 2007) and 7p, where two candidate WT suppressor genes, PTH1 and POU6F2, have been identified (Vernon et al., 2003; Perotti et al., 2004) .
Notwithstanding, until recently the precise genetic etiology of non-WT1-related WTs had remained largely undefined. Therefore, the recent report by Rivera et al. (2007) describing the discovery of a gene mapped to chromosome Xq11.1-termed WTX-that was found to be somatically inactivated in approximately one-third of nephroblastomas, represented a real breakthrough in the field of WT genetics. Detected alterations included gene loss in approximately 20% of cases and truncating mutations in another 10% and were reported to occur in similar percentages in male and female patients. Additional evidence of the involvement of WTX in the development of nephroblastomas was eventually provided by the molecular characterization of an apparently balanced translocation t(X;18) that resulted in the deletion of the gene in a WT from a male patient .
Due to its chromosomal localization, WTX has been proposed as a 'one-hit' tumor suppressor gene, since a single event is sufficient to inactivate the single copy present in males and the only functional allele on the active X chromosome (Xa) in females. Indeed, in five WTs from female patients that were investigated to ascertain the origin of the lost or mutated allele, it was the Xa to be invariantly affected .
In order to gather additional information on the actual involvement of WTX in the development of nephroblastoma, in the present study, we investigated 100 WT patients enrolled within a multicenter collaborative trial. Our results did not entirely confirm the findings by Rivera et al. (2007) and suggest that the actual involvement of WTX in WT may have been overestimated.
Results

Ascertainment of WTX gene losses
In total, 45 WTs from 43 male patients were investigated by real-time quantitative PCR (qPCR) to screen for deletions involving the WTX gene region, using two assays for the 5 0 and the 3 0 end of the gene. Genomic deletions were detected in five tumors (approximately 11%). In all cases, the deletion was identified by both assays employed, indicating the complete loss of the WTX gene (Figure 1) .
To investigate the occurrence of heterozygous somatic losses of the WTX gene in female cases, we checked for linked markers useful for discriminating between the maternal and paternal alleles. Two WTX-related microsatellites, Fam123b-1 and Fam123b-2, were found to be polymorphic, with observed frequencies of constitutional heterozygosity in analysed cases of 21% and 86%, respectively (data not shown). LOH for at least one of the two markers was identified in 9 of 50 informativethat is, constitutionally heterozygous for at least one locus-cases (18%), including one tumor (WT242) in which the deletion involved only one marker, with maintenance of heterozygosity for the other one ( Table 1) .
Localization of the WTX losses identified in female cases on the active or inactive chromosome X To verify whether the deletions involving WTX observed in WTs from female patients affected the Xa or the inactive X chromosome (Xi), we took advantage of the localization of the gene in the proximity of the androgen receptor (AR) gene, mapped more distally on Xq12, approximately 3.5 Mb apart. A HUMARA assay was performed on tumor and matched normal DNAs of the nine cases with WTX deletions. The analysis of not predigested normal and matched tumor DNAs, revealed constitutional heterozygosity in all but one (WT265) of the examined cases, with maintenance of heterozygosity at the tumor level in two cases (WT127 and 223) and LOH in the remaining six cases (WT124, 211, 232, 242, 256 and 259) , thus indicating that in the latter tumors the loss involving WTX extended to the AR gene (representative examples are shown in Figures 2a and b) . When the analysis was performed on tumor DNAs digested with methylation-sensitive enzymes prior to PCR amplification, a marked reduction of the signal of the retained allele was observed in all cases displaying LOH (Figure 2c ), consistently with the DNA being subject to enzymatic digestion and, therefore, unmethylated. Since methylation of the HUMARA locus correlates with X chromosome inactivation (Allen et al., 1992) , this finding indicates that in the investigated tumors the retained allele was localized on the Xa and the deletion involving both WTX and AR invariantly occurred on the Xi (Table 1) .
To further investigate the allelic origin of the genetic material lost on chromosome X, a sequence analysis of the CpG island located at the 5 0 end of the WTX gene was performed following DNA bisulfite modification. Normal female and male DNAs were used as controls (Figure 3) . In tumor DNA of case WT242, a single thymine signal was visible in correspondence of the cytosine residues of CpG sites, confirming the loss of the Xi assessed by the HUMARA assay. When the same analysis was applied to the WTs in which the localization of the lost WTX allele could not be ascertained with the HUMARA assay, in one case (WT265), the sequencing results where again consistent with the loss of the Xi, whereas in the remaining two cases (WT127 and 223), that is, those maintaining heterozygosity at the AR locus, the cytosine residues at CpG sites were found to be resistant to bisulfite modification, indicating the loss of Xa (Table 1) .
WTX mutation screening
Sequencing of the entire coding region of WTX was performed on the whole set of 57 WTs from female patients and on 40 WTs with no evidence of gene deletion from male patients. Nine previously unreported nucleotide changes were detected, including one frameshift, five missense mutations and three synonymous substitutions (Table 2 ). All variants were verified to be present also in the corresponding normal tissue (either normal kidney (NK) or peripheral blood leukocytes (PBL)), with the exception of the frameshift mutation. All but one of the nonsynonymous changes were identified in female patients.
The significance of the missense changes is at present undetermined. Among them, we detected two nonconservative amino acid changes (p.Y599C and p.R584G), and a substitution replacing a highly conserved glutamic . None of these were detected in 125 control subjects. These substitutions could warrant additional analyses to verify their functional consequences. Conversely, a disease causing role seems unlikely for the remaining alterations. These include p.P884L that was detected in one of 125 controls and, therefore, is likely to represent a rare neutral polymorphism, and p.I1003M, which introduces a conservative change in a nonevolutionary conserved residue. In keeping with the lack of clinical relevance, the latter mutation was present in one of the two tumors that lost the WTX allele on Xa and maintained Xi. As a consequence, the only mutation identified in 97 examined WTs that could be classified as frankly deleterious was the c.1670_1671delAG that introduces a premature translation termination signal at codon 578.
Total RNA was obtained from three of the WTs in which sequence variations were observed. The sequencing of the corresponding cDNAs revealed the expression of the variant allele only in case WT241 carrying the p.R584G mutation, whereas in tumor WT165 with the p.P884L mutation, only the wild-type allele appeared to be expressed, providing further support to the non pathogenic nature of this variant. Surprisingly, in tumor WT180, carrying the c.1670_1671delAG truncating mutation, sequencing analysis detected the presence of both the normal and the mutant transcript. However, that latter appeared to be present at a much lower level respect to the wild type, a finding that did not support its localization on the Xa (Figure 4) .
Overall, only in 2 of 10 WTs from female patients with partial or complete WTX gene loss or deleterious mutation, the detected alterations were found to affect the Xa.
WT1 and CTNNB1 mutation screening
The entire coding region of the WT1 gene and exon 3 of the CTNNB1 gene were sequenced in all WTs with WTX deletion or allelic variants. No mutation was detected.
Discussion
In the study by Rivera et al. (2007) , the notion that WTX is involved in the pathogenesis of WTs derived from a combination of different findings.
First, the relatively small size of the deletions detected using a high-density CGH array (70-kb medium resolution) on chromosome Xq11.1 in tumors from male patients, with only one to three probes being lost in each case and a common region of loss involving WTX alone. These results were eventually confirmed by both fluorescent in situ hybridization (FISH) and qPCR. However, when we used the latter approach to screen our group of WT male patients, we observed a frequency of gene loss (11%) that was approximately Second, interstitial chromosome deletions involving WTX were detected in 6 of 25 female WT cases (24%). Four of these were retested by combined DNA/RNA FISH analysis, using a probe for the Xi-coating transcript Xist, and in all of them the WTX loss was found to involve to the Xa . In our survey, WTs from female patients were screened by LOH, and WTX allelic deletions were detected in 9 of 50 informative cases, a frequency (18%), comparable to that reported by Rivera et al. (2007) . However, using a combination of HUMARA assay and bisulfite-modified DNA sequencing, we demonstrated that the lost allele derived from the Xa only in two cases. The finding that among our female WT cases, the overall frequency of WTX losses was twice as much as that detected in male patients, is in keeping with this occurrence being a random event, whose probability depends on chromosome X dosage.
Additional support to the involvement of WTX in WTs derived from the detection of inactivating somatic mutations in 6 of 82 examined cases (7%) . In contrast, all but one of the 97 WTs that we screened by direct sequencing tested negative for this type of alterations. Moreover, the only exception was represented by a tumor from a female patient carrying a truncating mutation, in which cDNA sequencing revealed a strongly reduced expression of the mutant respect to the wild-type allele, a finding not consistent with the localization of the mutation on the Xa. Taken together, we were able to assess a functional somatic nullizygosity of the WTX gene in only 7 WTs (5 from male and 2 from female patients) out of the 102 that were included in our study (7%), a frequency significantly different from that reported by Rivera et al. 2007 (15 of 51, 29%; P ¼ 0.0003, Fishers' exact test).
Our findings confirm the involvement of WTX in the development of WTs, but do not support the conclusions by Rivera et al. (2007) that the gene plays a role in a relevant fraction of these tumors. Furthermore, our results indicate that the detection of WTX loss or mutation in female patients always necessitates investigation to assess the status of the involved X chromosome.
We do not have an obvious explanation for the discrepancies between the two studies. The methodological approaches we used to analyse WTX losses in males and for the screening of intragenic mutations were the same employed by Rivera et al. (2007) . As for the other assays we applied, including LOH analysis, HUMARA assay and bisulfite-modified DNA sequencing, they are well-established methodologies and, certainly, are not more technically demanding than the FISH protocols developed by Rivera et al. (2007) to investigate WTX deletions in female cases. It is possible that WTX-related WTs constitute a defined subgroup of nephroblastomas with specific clinical and pathological characteristics, and by chance, these might have been differently represented in the two surveys. However, the number of such cases identified in our study was too small to allow investigating this hypothesis and no information on this regard is reported in the paper by Rivera et al. (2007) .
Recently, it has been reported that the WTX protein participates in the WNT/b-catenin signaling pathway (Major et al., 2007) , binding a multimeric protein complex to promote b-catenin downregulation. This provides an explanation for its tumor suppressor activity, since in the absence of functional WTX protein, b-catenin may translocate to the nucleus and promote the expression of genes involved in cell cycle control (Nusse, 2007) . Indeed, the involvement of the WNT pathway in WTs had been already documented, since approximately 15% of cases carry mutations of the CTNNB1 gene (Koesters et al., 1999; Maiti et al., 2000) .
Consistently with the notion that WTX and CTNNB1 function in the same cellular pathway, both in our study and in that by Rivera et al. (2007) , none of the WTXpositive tumors carried CTNNB1 mutations. Indeed, it might be possible that WTX mutations account for the subset of WTs exhibiting b-catenin nuclear immunoreactivity in the absence of CTNNB1 gene mutations (Koesters et al., 2003) . Interestingly, CTNNB1 mutations occur almost exclusively in WT1-mutant tumors (Maiti et al., 2000; Li et al., 2004) , suggesting that the No. of alleles carrying the identified variant on the total no. of tested alleles. Not previously reported synonymous changes included: c.12A>G, c.471G>A, and c.1611C>T.
Low frequency of WTX inactivation in Wilms' tumors D Perotti et al derangement of WNT pathway leads to the development of WT only in the absence of normal WT1 activity (Fukuzawa et al., 2006) . On this ground, it might be speculated that alterations of the WTX gene are responsible for the fraction of WT1-mutant WTs that do not carry CTNNB1 mutations (Maiti et al., 2000; Li et al., 2004) . At present, no data are available to verify this hypothesis, since in the report by Rivera et al. (2007) of the four WT1-mutant tumors that were investigated, none of which was found to be mutated in WTX, three were also positive for CTNNB1 mutations, and in our study none of the WTX-positive WTs carried WT1 mutations. Thus, the opposite possibility, that is, mutations in WT1 and WTX genes are alternative rather than complementary in the development of WTs (Huff, 2007) , cannot be definitely ruled out.
In conclusion, WTX may indeed represent a paradigmatic model for the study of the role of X-linked genes in human carcinogenesis ('one-hit' tumor suppressors), but its actual contribution to the total burden of WTs, particularly in female patients, and its interactions with known genes and pathways involved in the development of the disease, necessitate further evaluations.
Materials and methods
Patients and controls
The study involved patients consecutively enrolled from 2003 to date in the ongoing AIEOP WT trial and was approved by the Ethical Committee of the coordinating center (Istituto Nazionale Tumori, INT, Milan). An informed consent to the use of biological samples for the aim of the study was obtained from parents or legal tutors of all enrolled patients. The diagnosis of WT was confirmed by centralized histological revision. A total of 100 WT patients, 43 males and 57 females, were included. In two male patients with bilateral presentation, both tumors were available for molecular analyses. Control DNAs that were analysed for the presence of WTX variants identified in WT patients were obtained from blood donors collected through the internal service of INT. Both patients and controls were Caucasians and were enrolled within the Italian population.
Nucleic acid extraction DNA from tumor tissue, PBL and NK was extracted following the procedures already reported (Perotti et al., 2004) . RNA was extracted from selected tumor tissues using the Total Quick RNA Cells and Tissues kit (Talent, Trieste, Italy), and DNAse treated using the DNA-free kit (Ambion, Austin, TX, USA) in accordance with the manufacturer's instructions.
Real-time quantitative PCR analysis
Tumor DNAs from male patients were investigated using two TaqMan gene copy number assays (Applied Biosystems, Foster City, CA, USA), targeting a region located at the 5 0 end of the WTX gene (WTX5 0 , custom designed assay; forward primer, 5 0 -CCCTTCCCCAGGCTTTGG-3 0 ; reverse primer, 5 0 -CGGTGGCCTTGGAGTACTG-3 0 ; probe, 5 0 -CCCCATA CCCCCTCCC-3 0 ) and a region approximately 4.7 kb downstream the WTX termination codon, according to the cDNA sequence reported by Rivera et al. (2007) (FAM123B, assay ID: Hs01937181_s1). Both assays were checked for linear amplification using progressive amounts of control DNA. 0 -CTGGGTTTGGGATGCTGT-3 0 (forward) and 5 0 -CTGT GTCAAGGATGCATGC-3 0 (reverse). Amplified fragments were resolved on a 3130 Genetic Analyser (Applied Biosystems) and examined with the GeneMapper Software 4.0 (Applied Biosystems). In constitutionally heterozygous samples, the ratio between the peak height of the smaller allele and that of the larger allele in tumor DNA was calculated after normalization on the corresponding ratio in the matched PBL or NK DNA. A sample was scored positive for LOH when the computed value was o0.5 or >1.5.
HUMARA assay
The methylation status of the AR alleles in WTs with LOH in the WTX region was assessed using the method developed by Allen et al. (1992) with minor modifications. The assay is based on DNA digestion with the methylation-sensitive restriction endonucleases HpaII and HhaI followed by PCR amplification of the region containing both the polymorphic CAG repeat in the first exon of the AR gene and flanking recognition sites for the above enzymes. Only methylated DNA, which is resistant to enzymatic digestion, gives rise to an amplification product. The PCR forward primer was end labeled with fluorescent dye and amplification products were analysed as described above.
Analysis of WTX CpG island
The methylation status of the CpG island at the 5 0 end of the WTX gene (chromosomal position chrX:63340924-63342915) was investigated by bisulfite-converted DNA sequencing. Selected tumor DNAs were subject to bisulfite modification, which converts unmethylated cytosines into uracil, but leaves unaltered methylated residues, using the Epitect bisulfite kit, according to the manufacturer's instructions (Qiagen, Hilden, Germany). Modified DNAs were amplified by PCR and sequenced using the following primers 5 0 -GTTAGTATTTTT TAAGGGAAAAGGAGGTGAGG-3 0 (forward) and 5 0 -CC CTCCCCAAAAAAACTCAATTAAACCTAT-3 0 (reverse). These primers do not contain CpG sites and amplify bisulfite-modified DNA from both the Xa and Xi. PCR products were purified by ExoSAP-IT digestion (Amersham Biosciences, Piscataway, NJ, USA) and sequenced using the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems). Sequence reactions were examined on a 3100 Genetic Analyzer (Applied Biosystems), using the Sequencing Analysis 3.7 software (Applied Biosystems). Control female and male DNAs were used to ascertain the differentially methylated nucleotides on Xa and Xi.
Mutation screenings
The entire coding region of the WTX gene was PCR amplified from tumor DNAs into 12 overlapping fragments, using the primers reported by Rivera et al. (2007) , with minor modifications. PCR products were analysed as described above. Identified nucleotide variants were designated according to the international guidelines (Den Dunnen and Antonarakis, 2000) . The presence of previously unreported variants in tumor DNA was confirmed in independent PCR and sequencing reactions. Their occurrence in constitutional DNAs, as well as in 250 control alleles from blood donors was verified by amplification and sequencing of the specific DNA fragment where they localize. The WT1 and CTNNB1 genes were analysed as described (Perotti et al., 2005b; Rivera et al., 2007) .
Analysis of WTX allelic expression
In WTs in which unreported nucleotide variants were detected, 1 mg of DNAse-treated total RNA was reverse transcribed by random priming using the High Capacity cDNA Archive kit (Applied Biosystems). Obtained cDNA were amplified, using different combinations of reported WTX PCR primers , chosen accordingly to the specific fragment to analyse. Sequencing of the PCR products was performed as described above.
